Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal

Transplantation

Volumn 98, Issue 10, 2014, Pages 1105-1111

  Ohe, Hidenori ^a,c   Uchida, Yoichiro ^a,b   Yoshizawa, Atsushi ^a   Hirao, Hirofumi ^a   Taniguchi, Michiko ^c   Maruya, Etsuko ^c   Yurugi, Kimiko ^d   Hishida, Rie ^d   Maekawa, Taira ^d   Uemoto, Shinji ^a   Terasaki, Paul I ^c  

^a KYOTO UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

^c TERASAKI FOUNDATION LABORATORY   (United States)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Angiotensin II; DSA; Fibrosis; Liver transplantation; Tolerance

Indexed keywords

ANGIOTENSIN II TYPE 1 RECEPTOR ANTIBODY; HLA ANTIBODY; HLA DRB1 ANTIGEN; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; ANGIOTENSIN 1 RECEPTOR; HLA ANTIGEN;

ADULT; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DONOR; FEMALE; GRAFT DYSFUNCTION; HUMAN; IMMUNE DEFICIENCY; LIVER ALLOGRAFT FIBROSIS; LIVER TRANSPLANTATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CODING; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT RESPONSE; ADVERSE EFFECTS; BLOOD; CROSS-SECTIONAL STUDY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER CIRRHOSIS; LIVING DONOR; TRANSPLANTATION TOLERANCE;

ADULT; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HLA ANTIGENS; HLA-DRB1 CHAINS; HUMANS; IMMUNOSUPPRESSION; INFANT; ISOANTIBODIES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; RECEPTOR, ANGIOTENSIN, TYPE 1; TRANSPLANTATION TOLERANCE;

EID: 84927798387     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000185     Document Type: Article

References (42)

1. Auchincloss HJ. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001;1:6.
2. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72:449.
3. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009;50:1247.
4. Evans HM, Kelly DA, McKiernan PJ, et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43:1109.
5. Herzog D, Soglio DB, Fournet JC, et al. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008;14:946.
6. Ekong UD, Melin-Aldana H, Seshadri R, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl 2008;14:1582.
7. Scheenstra R, Peeters PM, Verkade HJ, et al. Graft fibrosis after pediatric liver transplantation: ten years of follow-up. Hepatology 2009;49:880.
8. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009;22:120.
9. Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009;15:S19.
10. Egawa H, Miyagawa-Hayashino A, Haga H, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res 2012;42:895.
11. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009;87:606.
12. Ohe H, Li Y, Nafady-Hego H, et al. Minimal but essential doses of immunosuppression: a more realistic approach to improve long-term outcomes for pediatric living-donor liver transplantation. Transplantation 2011;91:808.
13. Adeyi O, Alexander G, Baiocchi L, et al. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance (OT). Liver Transpl 2012;18:1154.
14. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986;2:165.
15. Mazariegos GV. Immunosuppression withdrawal after liver transplantation: what are the next steps? Transplantation 2011;91:697.
16. Bishop GA, Ierino FL, Sharland AF, et al. Approaching the promise of operational tolerance in clinical transplantation. Transplantation 2011;91:1065.
17. Londono MC, Danger R, Giral M, et al. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant 2012;12:1370.
18. Girnita A, Mazariegos GV, Castellaneta A, et al. Liver transplant recipients weaned off immunosuppression lack circulating donorspecific antibodies. Hum Immunol 2010;71:274.
19. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011;11:1868.
20. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012;18:1333.
21. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012;93:751.
22. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005;5:2611.
23. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008;86:1019.
24. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209.
25. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745.
26. Kurikawa N, Suga M, Kuroda S, et al. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003;139:1085.
27. Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002;36:1022.
28. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352:558.
29. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010;90:1473.
30. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983.
31. Kobayashi T, Maruya E, Niwa M, et al. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Hum Immunol 2011;72:11.
32. Ballardini G, Bianchi FB, Mirakian R, et al. HLA-A, B, C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol 1987;70:35.
33. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol 1990;162:165.
34. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008;86:1837.
35. Zhao X, Li Y, Ohe C, et al. Intragraft VC1 yC T cells with a unique T-cell receptor are closely associated with pediatric semiallogeneic liver transplant tolerance. Transplantation 2013;95:192.
36. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013;368:971.
37. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825.
38. Yasuda M, Shimizu I, Shiba M, et al. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999;29:719.
39. Ohe H, Waki K, Yoshitomi M, et al. Factors affecting operational tolerance after pediatric living-donor liver transplantation: impact of early post-transplant events and HLA match. Transpl Int 2012;25:97.
40. Burns JP. Research in children. Crit Care Med 2003;31:S131.
41. Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int 2012.
42. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696.